Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that a poster on Tonmya (cyclobenzaprine HCl sublingual tablets), investigated as TNX-102 SL, will be presented at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine (AAPM). The meeting is scheduled for March 5-8, 2026, in Salt Lake City, Utah, where the company will share data related to its investigational therapy as part of the scientific program. The presentation underscores Tonix's commitment to addressing fibromyalgia, a condition for which Tonmya recently became the first new treatment approved in over 15 years.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Tonmya (cyclobenzaprine HCl sublingual tablets 2.8 mg), the company's recently approved flagship medicine, represents a significant advancement for fibromyalgia patients. The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind Tonmya in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs highlight the company's broader strategy to address diverse therapeutic areas with significant unmet needs.
The presentation at the AAPM PainConnect Annual Meeting is a key opportunity for Tonix to engage with pain management specialists and share insights from its research. The meeting provides a platform for discussing the latest advancements in pain medicine, and Tonix's participation underscores the potential impact of Tonmya on the treatment landscape. For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.
Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. The company continues to invest in research and development to expand the therapeutic applications of its platform technologies. The full press release is available at https://ibn.fm/kwTPM.
